文献速递临床试验与 GCP基础与转化研究

丹红注射液在STEMI患者PCI术前或术后干预微血管阻塞的随机对照试验方案(DIRECTION研究)

Initiate Danhong Injection before or after percutaneous coronary intervention for microvascular obstruction in ST-elevation myocardial infarction (DIRECTION): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-01-08

DIRECTION研究是一项多中心、前瞻性、随机、评估者盲的试验方案,计划纳入336例接受经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者,随机分为常规治疗组、术前丹红注射液组或术后丹红注射液组。主要结局为PCI后90分钟ST段分辨率(STR)≥70%的比例,旨在评估丹红注射液预防微血管阻塞的疗效、安全性及最佳干预时机。

要点

  • 针对STEMI患者PCI围术期微血管阻塞(MVO)缺乏确证性治疗证据的问题,设计随机对照试验。
  • 主要结局指标为PCI后90分钟STR≥70%的比例,同时评估多项灌注、心功能及安全性指标。
  • 研究将比较术前与术后给予丹红注射液的疗效差异,以明确最佳干预时机。

核心结论

  • 该试验旨在评估丹红注射液预防STEMI患者PCI后微血管阻塞的疗效与安全性,并确定其最佳干预时机。

研究设计与样本

  • 多中心、前瞻性、随机、评估者盲的试验方案,计划纳入336例接受PCI的STEMI患者。
  • 患者随机分配至常规治疗组、术前丹红注射液组或术后丹红注射液组。

关键数值与推荐

  • 主要结局为PCI后90分钟ST段分辨率(STR)≥70%的比例。
  • 次要结局包括STR程度、TIMI血流分级、TIMI心肌灌注分级、左心室射血分数、N末端脑钠肽前体、高敏C反应蛋白及以心肌肌钙蛋白I和肌酸激酶MB曲线下面积表示的梗死面积。
  • 记录主要不良心血管事件和再入院事件,采用12条目简短健康调查评估健康质量。
  • 安全性结局包括出血事件、不良事件及血常规异常变化;心理状态和饮食模式分别采用汉密尔顿抑郁量表和食物频率问卷评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No treatment has convincingly been proven to be beneficial for microvascular obstruction (MVO) in patients with ST-elevation myocardial infarction (STEMI). Several studies have described the effects of Danhong Injection. However, evidence of a rigorously designed verification study is still lacking, and the intervention timing of Danhong Injection is uncertain. METHODS: The DIRECTION study is a multicenter, prospective, randomized, evaluator-blind study. A total of 336 patients with STEMI receiving percutaneous coronary intervention (PCI) will be randomly assigned to conventional treatment, the preoperative Danhong Injection, or the postoperative Danhong Injection. The primary outcome is rate of ST-segment resolution (STR) ≥ 70% at 90 min after PCI. The secondary outcomes are the degree of STR, Thrombolysis in Myocardial Infarction (TIMI) flow grade, TIMI myocardial perfusion grade, left ventricular ejection fraction, N-terminal prohormone brain natriuretic peptide, high-sensitivity C-reactive protein, and infarct size expressed as area under the curve for cardiac troponin I (cTnI) and for creatine kinase MB. The major adverse cardiovascular events and hospital readmission events will be recorded. Health quality will be assessed with the 12-item Short Form Health Survey. The safety outcomes include bleeding events, adverse events, and abnormal changes in routine blood tests. Psychological status and dietary patterns will be evaluated using Hamilton Depression Rating Scale and Food Frequency Questionnaire as the relevant indicators. DISCUSSION: This trial will evaluate the efficacy and safety of Danhong Injection, as well as its optimal timing of intervention to prevent MVO in patients with STEMI. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1900021440. Registered on February 21, 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang X, Tian G, Shi Z, et al. Initiate Danhong Injection before or after percutaneous coronary intervention for microvascular obstruction in ST-elevation myocardial infarction (DIRECTION): study protocol for a randomized controlled trial. Trials. 2020. PMID: 31915046. doi:10.1186/s13063-019-3947-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。